Nifty
:
18726.40
Sensex
:
63142.96
127.40 (0.69%)
350.08 (0.56%)
Nifty
Sensex
:
:
18726.40
63142.96
127.40 (0.69%)
350.08 (0.56%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
672.00
07-Jun-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 669.00
  • 674.75
  • 662.50
  • 664.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1398313
  •  9358.28
  •  674.75
  •  397.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 38,903.39
  • 20.18
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 37,086.15
  • 1.36%
  • 1.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.64%
  • 8.54%
  • FII
  • DII
  • Others
  • 23.02%
  • 14.85%
  • 1.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.89
  • 7.34
  • 0.51

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.68
  • 3.06
  • -2.06

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.59
  • 1.82
  • -2.54

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.78
  • 13.61
  • 12.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.41
  • 2.24
  • 1.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.80
  • 9.01
  • 8.29

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
6,472.96
5,809.37
11.42%
6,407.13
6,002.22
6.75%
5,739.37
5,941.92
-3.41%
6,235.92
5,701.98
9.36%
Expenses
5,470.78
4,834.97
13.15%
5,452.72
4,985.95
9.36%
4,948.58
4,755.20
4.07%
5,299.44
4,492.60
17.96%
EBITDA
1,002.18
974.40
2.85%
954.41
1,016.27
-6.09%
790.79
1,186.72
-33.36%
936.48
1,209.38
-22.57%
EBIDTM
15.48%
16.77%
14.90%
16.93%
13.78%
19.97%
15.02%
21.21%
Other Income
134.91
48.88
176.00%
92.65
64.99
42.56%
57.19
96.58
-40.78%
40.62
109.90
-63.04%
Interest
55.60
9.21
503.69%
44.96
16.13
178.74%
25.29
10.42
142.71%
14.63
12.88
13.59%
Depreciation
345.57
253.57
36.28%
321.40
299.05
7.47%
298.10
294.21
1.32%
279.51
279.69
-0.06%
PBT
735.92
597.74
23.12%
680.70
800.87
-15.00%
524.59
978.67
-46.40%
682.96
1,026.71
-33.48%
Tax
224.15
17.49
1,181.59%
189.10
189.49
-0.21%
112.99
270.91
-58.29%
158.61
247.74
-35.98%
PAT
511.77
580.25
-11.80%
491.60
611.38
-19.59%
411.60
707.76
-41.84%
524.35
778.97
-32.69%
PATM
7.91%
9.99%
7.67%
10.19%
7.17%
11.91%
8.41%
13.66%
EPS
8.64
9.84
-12.20%
8.38
10.32
-18.80%
6.99
11.90
-41.26%
8.88
13.14
-32.42%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
Net Sales Growth
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
 
Cost Of Goods Sold
11,293.26
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
Gross Profit
13,562.12
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
GP Margin
54.56%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
Total Expenditure
21,171.52
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
Power & Fuel Cost
-
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
% Of Sales
-
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
Employee Cost
-
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
% Of Sales
-
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
Manufacturing Exp.
-
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
% Of Sales
-
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
General & Admin Exp.
-
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
% Of Sales
-
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
Selling & Distn. Exp.
-
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
305.98
% Of Sales
-
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
5.23%
Miscellaneous Exp.
-
419.58
576.06
529.75
413.24
298.75
203.97
212.65
227.09
123.20
305.98
% Of Sales
-
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
2.55%
EBITDA
3,683.86
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
EBITDA Margin
14.82%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
Other Income
325.37
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
Interest
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
Depreciation
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
PBT
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
Tax
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
82.71
Tax Rate
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
PAT
1,939.32
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
PAT before Minority Interest
1,939.17
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
Minority Interest
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
PAT Margin
7.80%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
PAT Growth
-27.59%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
 
EPS
33.10
45.20
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02
5.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
Total Reserves
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
Non-Current Liabilities
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
Secured Loans
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
Unsecured Loans
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
Long Term Provisions
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
Current Liabilities
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
Trade Payables
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
Other Current Liabilities
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
Short Term Borrowings
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
Short Term Provisions
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
126.60
80.09
Total Liabilities
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
Net Block
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
Gross Block
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
Accumulated Depreciation
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
Non Current Assets
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
Capital Work in Progress
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
Non Current Investment
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
Long Term Loans & Adv.
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
237.82
Other Non Current Assets
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
Current Assets
18,122.69
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
Current Investments
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
Inventories
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
Sundry Debtors
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
Cash & Bank
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
Other Current Assets
1,987.72
601.29
489.35
1,919.82
1,977.28
1,596.81
831.25
659.57
448.46
407.69
Short Term Loans & Adv.
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
Net Current Assets
9,966.71
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
Total Assets
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
PBT
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
Adjustment
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
Changes in Working Capital
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
Cash after chg. in Working capital
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
Net Fixed Assets
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
Net Investments
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
Others
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
Cash from Financing Activity
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
Net Cash Inflow / Outflow
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
Opening Cash & Equivalents
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
Closing Cash & Equivalent
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
44.74
ROA
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
ROE
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
ROCE
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
Fixed Asset Turnover
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
Receivable days
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
Inventory Days
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
Payable days
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
57.79
Cash Conversion Cycle
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
134.00
Total Debt/Equity
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
Interest Cover
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Aurobindo Pharma reports 12% fall in Q4 consolidated net profit
    29th May 2023, 10:23 AM

    Total consolidated income of the company increased by 12.80% at Rs 6,607.87 crore for Q4FY23

    Read More
  • Aurobindo Pharma gets nod to sell stake in Auro Vaccines
    29th May 2023, 09:26 AM

    The Board of Directors of Aurobindo Pharma at its meeting held on May 27, 2023, has approved the same

    Read More
  • Aurobindo Pharma - Quarterly Results
    27th May 2023, 19:32 PM

    Read More
  • Aurobindo Pharma’s arm receives USFDA’s final approval for Carboprost Tromethamine Injection
    26th May 2023, 11:59 AM

    The product is expected to be launched in June 2023

    Read More
  • USFDA completes inspection at Unit XIV of Aurobindo Pharma
    20th May 2023, 11:04 AM

    The company has been issued a 'Form 483' with four observations

    Read More
  • Aurobindo Pharma inks voluntary license with Medicines Patent Pool
    31st Mar 2023, 14:36 PM

    The company has signed voluntary sub-licensing for developing and marketing Cabotegravir Tablets & Long Acting Injectables

    Read More
  • Aurobindo Pharma’s arm receives USFDA’s final approval for Lenalidomide Capsules
    8th Mar 2023, 12:58 PM

    The product is expected to be launched in October 2023

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.